Weight gain from novel antipsychotic drugs: need for action (Q33998440)

30 July 2017

1 reference

title

Weight gain from novel antipsychotic drugs: need for action (English)

1 reference

30 July 2017

1 reference

4

1 reference

30 July 2017

Green AI

1

1 reference

30 July 2017

Patel JK

series ordinal

2

1 reference

30 July 2017

Goisman RM

series ordinal

3

1 reference

30 July 2017

Blackburn G

series ordinal

5

1 reference

30 July 2017

publication date

1 July 2000

1 reference

General Hospital Psychiatry

30 July 2017

published in

1 reference

30 July 2017

volume

22

1 reference

30 July 2017

issue

4

1 reference

30 July 2017

page(s)

224-235

1 reference

Understanding the causes of schizophrenia

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Dependence on public financial support early in the course of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Suicide and schizophrenia: data from a prospective community treatment study

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Factors predicting suicide in psychotic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Induction of obesity by psychotropic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

The distribution of body mass index among individuals with and without schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Weight gain associated with neuroleptic medication: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Olanzapine: a new antipsychotic agent with efficacy in the management of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Bodyweight change as an adverse effect of drug treatment. Mechanisms and management

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

"Cognitive dysmetria" as an integrative theory of schizophrenia: a dysfunction in cortical-subcortical-cerebellar circuitry?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Is schizophrenia a progressive neurodevelopmental disorder? Toward a unitary pathogenetic mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

The Genetics of Schizophrenia is the Genetics of Neurodevelopment

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

The ontogeny of human gyrification

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Long-term Course of Hospitalization for Schizophrenia: Part I. Risk for Rehospitalization

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Attention and higher cortical functions in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Neuropsychological function in schizophrenia. Selective impairment in memory and learning

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Cognitive rehabilitation for schizophrenia: is it possible? Is it necessary?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Excess mortality of schizophrenia. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Suicide in schizophrenics, manics, depressives, and surgical controls. A comparison with general population suicide mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Overview: maintenance therapy in psychiatry: I. Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Risperidone in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Should clozapine be a first-line treatment for schizophrenia? The rationale for a double-blind clinical trial in first-episode patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Decreased substance use in chronically psychotic patients treated with clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Early detection and intervention in schizophrenia: research

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Body-weight changes in psychiatric illness; a critical survey of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Experiences with large scale interhospital cooperative research in chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Prevalence of obesity in patients receiving depot antipsychotics

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

The distribution of adipose tissue in female in-patients receiving psychotropic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Cardiovascular and respiratory risk factors and symptoms among general practice patients with long-term mental illness.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Novel antipsychotics and new onset diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Clozapine-induced weight gain: prevalence and clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Serum leptin levels increase rapidly after initiation of clozapine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Weight gain among schizophrenic patients treated with clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Differential effect of clozapine on weight: a controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Neuroleptics and the Natural Course of Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Measurement of appetite disturbances in psychiatric disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Overweight and obesity in the United States: prevalence and trends, 1960-1994

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Diabetes mellitus in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Descriptive epidemiology of body weight and weight change in U.S. adults

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Key issues in the prevention of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Weight gain as a risk factor for clinical diabetes mellitus in women

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Development of the multiple metabolic syndrome: an epidemiologic perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

The prevention and treatment of obesity. Application to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Effect of degree of weight loss on health benefits

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

1 reference

7 January 2021

Role of insulin resistance in human disease (syndrome X): an expanded definition

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Weight gain and the risk of developing insulin resistance syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

American Heart Association call to action: obesity as a major risk factor for coronary heart disease. AHA Nutrition Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

The treatment and prevention of obesity: a systematic review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Metabolic and weight-loss effects of a long-term dietary intervention in obese patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Physical activity and long-term maintenance of weight loss

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Preventing relapse in obesity through posttreatment maintenance systems: comparing the relative efficacy of two levels of therapist support.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Lifestyle modification in the pharmacologic treatment of obesity: a pilot investigation of a potential primary care approach.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Weight loss with psychiatric residents in a behavioral self control program

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

A study of weight reducing diets in psychiatric in-patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Reinforcement and weight loss in schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Effectiveness of clozapine and a social learning program for severely disabled psychiatric inpatients.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Training hospitalized patients with schizophrenia in community reintegration skills

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Optimal drug and behavior therapy for treatment-refractory schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Improvements in blood pressure, glucose metabolism, and lipoprotein lipids after aerobic exercise plus weight loss in obese, hypertensive middle-aged men.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Moderate-intensity aerobic training improves glucose tolerance in aging independent of abdominal adiposity.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Effect of exercise training on insulin sensitivity and glucose metabolism in lean, obese, and diabetic men

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Benefits of lifestyle activity vs structured exercise

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Environmental and policy interventions to promote physical activity

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Report on the NIH Workshop on Pharmacologic Treatment of Obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Determinants of response to anorexiants.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Sibutramine produces dose-related weight loss

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Phentermine, psychosis, and family history

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Phentermine and psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Letter: Fenfluramine and psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Delirium with manic symptoms induced by diet pills.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Amphetamine-like reactions to phenylpropanolamine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Psychotic reaction caused by proprietary oral diet agents

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Sibutramine: a novel new agent for obesity treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

A double-blind randomized placebo-controlled trial of sibutramine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Long-term weight control study: conclusions

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Pharmacological treatment of obesity: present status

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Obesity: a time bomb to be defused

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

1 reference

7 January 2021

The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

INTENSIVE TREATMENT OF PSYCHOTIC BEHAVIOUR BY STIMULUS SATIATION AND FOOD REINFORCEMENT.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Rapid Treatment of Gross Obesity by Operant Techniques

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

Use of personal trainers and financial incentives to increase exercise in a behavioral weight-loss program

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2800%2900081-5

7 January 2021

10.1016/S0163-8343(00)00081-5

Identifiers

DOI

1 reference

30 July 2017

1 reference